{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:18:50Z","timestamp":1763986730010},"reference-count":79,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T00:00:00Z","timestamp":1396915200000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metastatic melanoma remains one of the major causes of death related to skin cancers and has been resistant to traditional anticancer therapies. The clinical development of vemurafenib in the treatment of metastatic melanoma with the <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>600 mutation of the <jats:styled-content style=\"fixed-case\"><jats:italic>BRAF<\/jats:italic><\/jats:styled-content> gene has provided meaningful improvements in the overall survival and progression\u2010free survival of metastatic melanoma patients. However, significant side effects have been noted with this therapy, in particular cutaneous adverse events (<jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>) such as rashes, squamous cell carcinoma and severe photosensitivity to <jats:styled-content style=\"fixed-case\">UVA<\/jats:styled-content> light among others. With an emphasis on the <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ustralian perspective, this review provides an overview of the clinical development of vemurafenib, its attendant dose\u2010limiting toxicities and other <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>, recommendations for safety monitoring, supportive treatments of <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content> and dose modifications, with the aim of maximizing the chances of continuing beneficial treatment.<\/jats:p>","DOI":"10.1111\/ajco.12200","type":"journal-article","created":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:58:44Z","timestamp":1397005124000},"page":"1-15","source":"Crossref","is-referenced-by-count":5,"title":["The use of vemurafenib in <scp>A<\/scp>ustralian patients with unresectable or metastatic melanoma containing the <scp>V<\/scp>600 <scp><i>BRAF<\/i><\/scp> gene mutation"],"prefix":"10.1111","volume":"10","author":[{"given":"Michael P","family":"Brown","sequence":"first","affiliation":[{"name":"Cancer Clinical Trials Unit Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,8]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"357","article-title":"Early detection and treatment of skin cancer","volume":"62","author":"Jerant AF","year":"2000","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.69"},{"key":"e_1_2_8_5_1","volume-title":"GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10","author":"Ferlay J","year":"2010"},{"key":"e_1_2_8_6_1","volume-title":"Australian Cancer Incidence and Mortality (ACIM) Books: Melanoma of the Skin","author":"Australian Institute of Health and Welfare","year":"2014"},{"key":"e_1_2_8_7_1","unstructured":"Australian Government Department of Environment.Indicator: A\u201015 Skin melanoma rates.2000. [Accessed 26 Feb 2014.] Available from URL:http:\/\/www.environment.gov.au\/node\/22250."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2012.10.002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4327"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.056"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0505-OA"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.07.003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.143"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112302"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e3283532565"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0052"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70051\u20108"},{"key":"e_1_2_8_24_1","first-page":"866","article-title":"Significant long\u2010term survival benefit demonstrated with vemurafenib in ongoing Phase I study","volume":"25","author":"Kim K","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"e_1_2_8_25_1","first-page":"866","article-title":"Long term safety and efficacy of vemurafenib in the treatment of BRAFV600\u2010mutant advanced melanoma (BRIM\u20102 study update)","volume":"25","author":"Kim K","year":"2012","journal-title":"Melanoma Res"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.019"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","unstructured":"ChanM HayduL MenziesAMet\u2009al.Clinical characteristics and survival of BRAF\u2010mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD).2013. ASCO Meeting Abstracts 2013 31 9062.","DOI":"10.1200\/jco.2013.31.15_suppl.9062"},{"key":"e_1_2_8_28_1","unstructured":"The Royal Marsden.Vemurafenib. [Accessed 16 Oct 2013.] Available from URL:http:\/\/www.royalmarsden.nhs.uk\/research\/highlights\/pages\/vemurafenib.aspx."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08833"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00685.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08902"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105358"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.125"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04546.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2012.48.2.1745274"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7680"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8594"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e3182604873"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1660"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12094"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.5572"},{"key":"e_1_2_8_42_1","first-page":"847","article-title":"Development of colonic adenomas and gastric polyps in BRAF\u2010mutant melanoma patients treated with vemurafenib","volume":"25","author":"Chapman P","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.881471"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.4118"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208958"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32836124aa"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds292"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1113752"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12119"},{"key":"e_1_2_8_50_1","first-page":"133","article-title":"Cutaneous side effects of new antitumor drugs","volume":"109","author":"Gutzmer R","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058721"},{"key":"e_1_2_8_52_1","first-page":"696","article-title":"Increased frequencies of circulating myeloid\u2010derived suppressor cells (MDSC) in melanoma patients: an early event in melanoma disease leading to general immunosuppression","volume":"10","author":"Rudolph BM","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12010"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.015"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.038"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70413-8"},{"key":"e_1_2_8_57_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1684\/ejd.2013.1991","article-title":"Vemurafenib\u2010induced panniculitis","volume":"23","author":"Villani AP","year":"2013","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1684\/ejd.2012.1915","article-title":"Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma","volume":"23","author":"Degen A","year":"2013","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_59_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D370X41670","article-title":"Vemurafenib\u2010associated neutrophilic panniculitis: an emergent adverse effect of variable severity","volume":"19","author":"Maldonado\u2010Seral C","year":"2013","journal-title":"Dermatol Online J"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283570792"},{"key":"e_1_2_8_61_1","first-page":"S132","article-title":"Neutrophilic dermatoses associated with vemurafenib","volume":"132","author":"Novoa RA","year":"2012","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2842"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamadermatol.23"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.008"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0333"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.01.015"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.737780"},{"issue":"20","key":"e_1_2_8_68_1","doi-asserted-by":"crossref","first-page":"e20041","DOI":"10.1200\/jco.2013.31.15_suppl.e20041","article-title":"Vemurafenib\u2010associated bullous DRESS syndrome: a very severe cutaneous reaction","volume":"31","author":"Gey A","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.7028"},{"issue":"1","key":"e_1_2_8_71_1","first-page":"118","article-title":"Vemurafenib (BRAF inhibitor) associated uveitis in patients with metastatic cutaneous melanoma","volume":"40","author":"Sandhu SS","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"e_1_2_8_72_1","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM\u20102: an open\u2010label, multicentre phase II study of vemurafenib in previously treated patients with BRAFV600E mutation positive Melanoma. abstract","volume":"29","author":"Ribas A","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_73_1","unstructured":"SufficoolK HepperD HurstEet\u2009al.Development of melanocytic proliferations including new primary malignant melanomas during treatment with vemurafenib a selective BRAF inhibitor[Abstract]. 2013 Annual Meeting American Society of Dermatopathology.2013."},{"key":"e_1_2_8_74_1","first-page":"AB142","article-title":"Treatment of vemurafenib\u2010related cutaneous side effects with acitretin","volume":"68","author":"Chon S","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_8_75_1","unstructured":"Roche Australia.Zelboraf Product Information.2014. Available from URL:http:\/\/www.roche\u2010australia.com\/home\/products\/pharmaceuticals\/zelboraf.html[Accessed 28 March 2014.]"},{"key":"e_1_2_8_76_1","unstructured":"Food and Drug Administration.Center for Drug Evaluation and Research: application number 202429Orig1s000 clinical pharmacology and biopharmaceutics review(s). pp.27\u201331. [Accessed 15 Oct 2013.] Available from URL:http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm."},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302338"},{"issue":"20","key":"e_1_2_8_78_1","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1200\/jco.2013.31.15_suppl.9035","article-title":"Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of ipilimumab EAP","volume":"31","author":"Ascierto PA","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4200"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7755"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12200","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:30:41Z","timestamp":1694615441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":79,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/ajco.12200"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12200","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}